ANGLE plc (ANPCY: OTCQX International) | MD Anderson Cancer Center Research Demonstrates Clinical Applicability of ANGLE plc’s ‘Blood Biopsy’ Technology

OTC

MD Anderson Cancer Center Research Demonstrates Clinical Applicability of ANGLE plc’s ‘Blood Biopsy’ Technology

Aug 02, 2016

OTC Disclosure News Service

ANGLE plc (AIM:AGL OTCQX:ANPCY), the UK-based medical diagnostics
company with pioneering products for cancer diagnostics and fetal
health, announces a poster presentation by researchers from the
University of Texas MD Anderson Cancer Center describing
clinically-relevant results from a study using its lead product, the Parsortix
cell separation system, to harvest breast cancer cells in blood for
subsequent molecular characterization. The poster will be presented at
the American Association for Clinical Chemistry Annual Meeting July 31 –
August 4.

The research team, led by Dr. James M. Reuben, Professor, Department of
Hematopathology, MD Anderson Cancer Center, confirmed the ability to
perform advanced molecular analysis on breast cancer cells isolated from
blood samples using the Parsortix liquid biopsy technology. The
researchers note the ability of the Parsortix method to harvest
circulating tumor cells (CTCs) without the use of antibodies.

In the study, entitled “Antibody-free microfluidics-based circulating
tumor cell enrichment by ANGLE plc Parsortix and downstream molecular
characterization by Affymetrix branched DNA technology“, the researchers
describe the advantages of being able to perform gene expression
analysis on the harvested cells.

Following capture of breast cancer cells that were spiked into healthy
donor blood samples, the researchers measured the expression of several
genes, including specific breast-cancer related genes. The study results
show high specificity for detection of the targeted genes and strong
sensitivity for highly expressed genes in dilutions of the harvested
cell extracts. The ability to measure gene expression in CTCs has the
potential to provide more clinically actionable information than simple
detection or quantification of tumor cells in blood.

This new research demonstrates the potential to obtain particularly
detailed information from CTCs regarding the cells being analysed.
Liquid biopsy using the Parsortix system, combined with molecular
characterization of the CTCs, can be repeated over time without
requiring surgical removal of a tumor sample. It offers a less invasive
and more personalized approach to monitoring for response to therapy and
disease progression.

“Multiplexed gene expression analysis will be a very important approach
in enabling new clinical diagnostic capability in oncology through
liquid biopsy. But this is technically demanding, and the most leading
edge techniques will need to be applied with CTCs if liquid biopsy is to
be robust and versatile. CTC analysis using array based methods is an
area of particular interest to us, and this research is an important
step in proving their efficacy with our cell separation system, and in
developing the required methodology. Coming as they do from the renowned
MD Anderson Cancer Center, these developments and conclusions are
encouraging and exciting,” said ANGLE Chief Technology Officer, Shane
Booth.

About ANGLE plc

ANGLE is a UK-based specialist medtech company commercializing the
Parsortix system, a cell separation technology that enables a simple
blood test to capture targeted cells for investigation, such as
circulating tumor cells (CTCs) for molecular profiling and analysis.
Parsortix can help deliver targeted cancer diagnostics that has the
potential to inform personalized treatment of cancer. It is also
designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular drug
and then monitoring the drug’s effectiveness. ANGLE has established
formal collaborations with world-class cancer centers and is working
with these cancer centers to demonstrate key applications for its
Parsortix non-invasive cancer diagnostic system as a liquid biopsy. In
addition to cancer cells, the Parsortix technology has the potential for
deployment for other clinically significant cell types in the future.

ANGLE is a public company trading on the AIM market of the London Stock
Exchange under the ticker symbol AGL and on the OTCQX market in the US
under the ticker symbol ANPCY. For more information, www.angleplc.com

Copyright © 2016 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply